Toronto Memory Program

12/30/2025

Trontinemab is one of the latest disease-modifying drugs currently being tested in late-stage clinical trials. Here’s what we know about this potential new treatment for Alzheimer's disease.

12/18/2025

🎄 Holiday Hours at Toronto Memory Program 🎄

Please note that TMP will be closed on Christmas Day, Boxing Day, and New Year’s Day.

We wish you and your loved ones a wonderful holiday season filled with warmth, health, and joy. 💫

12/04/2025

Making healthy choices can help you avoid many chronic diseases and can even lower your risk of severe illness from some infectious diseases, such as the flu and COVID-19. But healthy behaviors are only part of the picture. Getting routine preventive care can help you stay well and catch problems early.

Knowing your family health history can help you stay well and catch problems early.

11/27/2025

It’s not quite winter yet, but it is sure starting to look like it. As the colder weather sets in, many older adults find it harder to stay active and connected — but this time of year also brings wonderful opportunities to enjoy safe, meaningful, and enriching activities.

Here are a variety of ideas to stay engaged this season:
• Short outdoor walks on clear days
• Feeding winter birds
• Indoor stretching, yoga, or gentle exercise videos
• Cooking, baking, or trying a new winter recipe
• Reading, audiobooks, or joining a book club
• Puzzles, crosswords, card games, or board games
• Knitting, sewing, or other creative crafts
• Painting, drawing, or adult colouring
• Organizing old photos or creating a memory album
• Listening to music or learning a musical instrument
• Journaling or writing letters to loved ones
• Virtual or phone catch-ups with friends and family
• Watching documentaries or educational series
• Exploring online classes in history, languages, or art
• Indoor gardening or caring for houseplants

Small, enjoyable activities can make the months ahead brighter and support both physical and cognitive health.

11/18/2025

On November 12, 2025, Dr. Sharon Cohen—Founder and Medical Director of Toronto Memory Program—joined the Alzheimer Society of Huron-Perth to deliver her talk, “A New Era: 2025 Update on Diagnosis and Treatment of Alzheimer’s Disease.” Dr. Cohen provided a comprehensive update on emerging research that is reshaping the dementia treatment landscape in Canada.

In her presentation, she discussed the progression and risk factors for dementia, promising new treatments currently in Phase III clinical trials, the impact of brain-healthy lifestyle choices, and the critical importance of participation in clinical trials.

Alzheimer Society Huron Perth - 2025 Dementia Research Night. On November 12, 2025, Dr. Sharon Cohen, founder and Medical Director of the Toronto Memory Prog...

11/13/2025

Today, our Medical Director and Behavioural Neurologist, Dr. Sharon Cohen, had the pleasure of presenting to the wonderful community at Extended Learning Opportunities (ELO) in Erin, Ontario — a volunteer-run lifelong learning group dedicated to bringing educational events to their community.

Dr. Cohen delivered A New Era: 2025 Update on Alzheimer’s Diagnosis & Treatment — a timely and inspiring session highlighting how far we’ve come in understanding, diagnosing, and treating Alzheimer’s disease.

With Canada’s first disease-slowing treatment for Alzheimer’s now approved, this truly is a historic moment. More individuals are seeking early assessment, new diagnostic tools (including blood tests) are becoming available, and community education has never been more important.

We loved connecting with this thoughtful, engaged audience and having the chance to answer their questions.

A meaningful day of learning, hope, and progress — and we’re grateful to be part of it.

11/04/2025

Alzheimer’s disease drug Leqembi has received approval in Canada for treating early-stage Alzheimer’s disease. Our Medical Director, Dr. Sharon Cohen, who was involved in the Eisai clinical trials, spoke with Being Patient about what this milestone means for Canadian patients — including next steps for access, coverage, and ongoing data collection to confirm real-world benefits.

Alzheimer’s drug Leqembi will soon be available in Canada, but it isn’t clear whether it will be covered by public health insurance.

10/31/2025

No tricks, just treats - and maybe a few clinical trials! 🎃👻

10/30/2025

Dr. Sharon Cohen, Medical Director of Toronto Memory Program, joined Fight Back with Libby Znaimer to discuss lecanemab, a new Alzheimer's disease drug just approved by Health Canada. Dr. Cohen was involved in the clinical trials of the drug as a Principal Investigator. To catch the full interview, visit zoomerradio.ca/podcasts.Iifator

10/28/2025

Toronto Memory Program Medical Director and Neurologist Dr. Sharon Cohen discusses on CTV News the Alzheimer’s drug that targets the underlying cause of the disease and key findings from the clinical trials.

Neurologist Dr. Sharon Cohen speaks on the Alzheimer's drug that targets the underlining cause of the disease and what was discovered during clinical trials....

10/27/2025

Health Canada has officially approved lecanemab (Leqembi) — the FIRST treatment in Canada proven to slow the progression of early Alzheimer’s disease!

At Toronto Memory Program, we are incredibly proud of our clinical trial participants, study partners, and dedicated research team who helped make this milestone possible. Their commitment and courage have directly contributed to bringing this treatment to Canadians.

This is a day of hope, progress, and renewed energy for all those affected by Alzheimer’s disease.

10/21/2025

New here? Welcome to Toronto Memory Program!

We’re advancing Alzheimer’s disease prevention and treatment through compassionate care, innovative research, and education.

Who We Are:
Based in North York, our 60+ staff specialize in Alzheimer’s disease and related cognitive disorders—bridging clinical care and research to bring new treatments forward.

Our Mission:
To educate the public on early detection, promote participation in clinical trials, reduce barriers to diagnosis through free testing, and empower patients and families through education and access.

Meet Our Director:
Dr. Sharon Cohen, Cognitive & Behavioural Neurologist, Director, and global leader in Alzheimer’s disease clinical research.

Our Research Program:
As Canada’s largest Alzheimer’s disease clinical trial site, we’ve conducted more than 185 studies across all phases.

Benefits of Participation:
No-cost study care, regular health monitoring, and access to innovative therapies—helping move science forward for future generations.

Get Involved:
We are all impacted by Alzheimer’s disease. Join us, share our mission, and help move research forward.